Post on 06-May-2015
transcript
Calcium disorders
Roderick WarrenRegistrar teaching
Buckfastleigh, July 2014
Calcium homeostasis
Please see the handout (assuming I remembered it)
Vitamin D from skin and diet 25-hydroxylase
25(OH)-D – inactive (?)
1-OHase
PTH effects on the kidney1.Stimulates activation of vit D.2.Promotes phosphate excretion.3.Reduces calcium resorption.
1,25(OH)2-D effects on kidneyIncreases Ca resorption
1α-hydroxylationStimulated by Inhibited by PTH 1,25(OH)2-D Low PO4 High PO4
PTH effect on boneCalcium export
PTH productionMain stimulus is low Ca2+.Inhibited by 1,25(OH)2-D.Mg required.
Calcitonin productionMain stimulus high Ca2+ (ionized>1.15) – also glucagon, gastrin, ß-adrenergic agonists (?reason for low Ca in acute illness)
Calcitonin effects on bone• inhibits osteoclast
resorption• thereby lowers Ca and PO4
• no effect on Mg
1,25(OH)2-D effects on gutIncreases Ca2+ and PO4
absorption
Vit D direct effect on bone?Unclear
Parathyroid hormone
Calcitonin
1,25-OH2-D
Hypercalcaemia
Question
Sue has this:• Calcium 3.4 mmol/L• PTH 0.6 pmol/l (1.6-6.9)
What are the differential diagnoses?
Answer
Sue has this:• Calcium 3.4 mmol/L• PTH 0.6 pmol/l (1.6-6.9)
Diagnosis could include:• Cancer• Vit D poisoning• Granulomatous disease etc
Causes of hypercalcaemia
Malignancy 90% ofPrimary hyperparathyroidism all cases
Other causesFamilialDrugs: lithium, thiazides, activated vitamin DGranulomatous diseases: sarcoid etcMilk alkali syndromeHyperthyroidismProlonged immobilisation
Malignancy causing hypercalcaemia
Cancer site Mechanism Lung PTH-rp (80%) Breast Bony mets (20%) Haematological e.g. myeloma Head and neck Renal Prostate Unknown GI
PTH-related peptide
Fetal equivalent of PTH Maintains fetal sCa slightly higher than maternal
Activates PTH receptor Typical pattern is - high calcium - low phosphate
High phosphate suggests non PTH/PTHrp cause
Is this hypercalcaemia due to cancer?
Low PTH - Cancer until proven otherwise: - Serum electrophoresis, Bence Jones - Tumour markers (PSA etc) - CT TAP - Bone scan - Endoscopy
Normal or high PTH - Almost certainly not cancer - rarely tumours co-secrete PTH and PTH-rp - parathyroid carcinoma
Question
Bob has this:• Calcium 2.9 mmol/L• Phosphate 2.4 mmol/L• PTH 42 pmol/l (1.6-6.9)
What are the differential diagnoses?
Answer
Bob has this:• Calcium 2.9 mmol/L• Phosphate 2.4 mmol/L• PTH 42 pmol/l (1.6-6.9)
Diagnosis could include:• CKD with tertiary hyperparathyroidism
Hyperparathyroidism
Primary SecondaryParathyroid adenoma Renal failure
Impaired PO4 excretionHigh PTH Impaired Vit D activation
High calcium High PTHLow phosphate Normal or high phosphate
Normal or low calcium
Hyperparathyroidism
Primary SecondaryParathyroid adenoma Renal failure
Impaired PO4 excretionHigh PTH Impaired Vit D activation
High calcium High PTHLow phosphate Normal or high phosphate
Normal or low calcium
Vitamin D from skin and diet 25-hydroxylase
25(OH)-D – inactive (?)
1-OHase
PTH effects on the kidney1.Stimulates activation of vit D.2.Promotes phosphate excretion.3.Reduces calcium resorption.
1,25(OH)2-D effects on kidneyIncreases Ca resorption
1α-hydroxylationStimulated by Inhibited by PTH 1,25(OH)2-D Low PO4 High PO4
PTH effect on boneCalcium export
PTH productionMain stimulus is low Ca2+.Inhibited by 1,25(OH)2-D.Mg required.
Calcitonin productionMain stimulus high Ca2+ (ionized>1.15) – also glucagon, gastrin, ß-adrenergic agonists (?reason for low Ca in acute illness)
Calcitonin effects on bone• inhibits osteoclast
resorption• thereby lowers Ca and PO4
• no effect on Mg
1,25(OH)2-D effects on gutIncreases Ca2+ and PO4
absorption
Vit D direct effect on bone?Unclear
Parathyroid hormone
Calcitonin
1,25-OH2-D
1y hyperparathyroidism - epidemiology
AgeIncreases with age90% aged over 50
GenderFemale preponderance 70-80%
1y hyperparathyroidism - epidemiology
PrevalenceIncreasing
Tayside6 per 1000 population.About 20 per 1000 in women age >50. (Defined as Ca>2.55).
Mirrors increased calcium testing. (Calcium testing increased from 5% to 15% of population each year).
CaliforniaAbout 4 per 1000 in older women (Defined as Ca>2.6.)
Yu et al, Clin Endo 2009, 71, 485-493. Yeh et al, JCEM 2013, 98, 1122-1129.
1y hyperparathyroidism - epidemiology
How common is it really? In older women – 0.5 to 2% prevalence Based on 15% of population having blood tests
What would it be if 100% of population were tested?
1y hyperparathyroidism - diagnosis
Elevated calciumElevated or non-low PTHNot secondary to renal failure High phosphate eGFR<60
Question
Mary has this:• Calcium 2.75 mmol/L• PTH 18.2 pmol/L
What are the differential diagnoses?
Answer
Mary has this:• Calcium 2.75 mmol/L• PTH 8.2 pmol/L• Vitamin D 15 nmol/L
Diagnosis could include:• Primary hyperparathyroidism with vit D deficiency• Familial hypercalcaemia with vit D deficiency
1y hyperparathyroidism - diagnosis
Elevated calciumElevated or non-low PTHNot secondary to renal failure High phosphate eGFR<60Not due to drugs Thiazides LithiumNot due to vitamin D deficiency
Effect of vitamin D on PTH
Vitamin D insufficiency causes secondary hyperparathyroidism
PTH on Y-axis is approx 2-11 pmol/L
Vit D on X-axis is approx 0 to >75 nmol/L
Vitamin D from skin and diet 25-hydroxylase
25(OH)-D – inactive (?)
1-OHase
PTH effects on the kidney1.Stimulates activation of vit D.2.Promotes phosphate excretion.3.Reduces calcium resorption.
1,25(OH)2-D effects on kidneyIncreases Ca resorption
1α-hydroxylationStimulated by Inhibited by PTH 1,25(OH)2-D Low PO4 High PO4
PTH effect on boneCalcium export
PTH productionMain stimulus is low Ca2+.Inhibited by 1,25(OH)2-D.Mg required.
Calcitonin productionMain stimulus high Ca2+ (ionized>1.15) – also glucagon, gastrin, ß-adrenergic agonists (?reason for low Ca in acute illness)
Calcitonin effects on bone• inhibits osteoclast
resorption• thereby lowers Ca and PO4
• no effect on Mg
1,25(OH)2-D effects on gutIncreases Ca2+ and PO4
absorption
Vit D direct effect on bone?Unclear
Parathyroid hormone
Calcitonin
1,25-OH2-D
How could vitamin D deficiency be relevant in a hypercalcaemic patient?
Theoretically (and, very occasionally, for real):
• PTH is too high for FHH• Vit D replacement lowers PTH• PTH now plausible for FHH
Is vitamin D replacement safe inprimary hyperparathyroidism?
Wagner Das Tucci Grey
N 35 16 56 21
Vit D baseline 36 29 36.4 28
Vit D final 105 71.8 88.6 77
Calcium baseline 2.69 2.75 2.74 2.70
Calcium final 2.60 2.65 2.73 2.69
PTH baselineUnchanged
18.6 15.3 12.4
PTH final 18.0 14.1 9.2
Problem patients None None None None
Wagner Endocr Pract 2013, 19(3), 420-5. Das, Endocr Abstr 2014, 34, P6. Tucci EJE 2009, 161, 189. Grey, JCEM 2005 90(4) 2122.
Local anecdotal reports of hypercalcaemia. Could this be due to natural variation? CV around 4% i.e. not unusual to see +/- 0.2 mmol/L.
Parathyroid bone disease
Osteoporosis• Decreased BMD in PHPT patients• Rate of bone less similar to normal population
Fracture• 1.5-fold increase in all fractures PHPT• 3-fold vertebra• 2-fold forearm• 1.5-fold hip
Parathyroid bone disease
Left – sub-periosteal erosionsAbove – bands of osteosclerosis “rugby jersey” appearanceRight – above, metaphyseal erosion in adolescence, and below, after vit D treatment
Cundy, Ulst Med J 1985, 54, S34-43
Brown tumoursOsteitis fibrosa cystica
Wikipedia
Primary hyperparathyroidismInvestigations
Bloods Calcium (high). Phosphate (low or low-normal). PTH (high or normal). Liver (alk phos often high but not diagnostic). Vitamin D (usually low and very occasionally confounds diagnosis).
Urine 24-hour urine calcium indices (see later).
Renal USS Only in patients with history suggestive of stones.
DEXA May influence surgery, or prompt bisphosphonate treatment.
Question
Jemima has this:• Age 79• No symptoms• Calcium 2.71 mmol/L• PTH 7.2 pmol/L• Vit D 50 nmol/L• 24-hr urine Ca 6.8 mmol• eGFR 51• DEXA T -2.7 Z -0.2 at spine
What treatment?
Answer
Jemima has this: What treatment?• Age 79 Looks like PHPT• No symptoms Osteoporosis• Calcium 2.71 mmol/L• PTH 7.2 pmol/L• Vit D 50 nmol/L Really not keen on surgery• 24-hr urine Ca 6.8 mmol “Why do I need an op doc?”• eGFR 51• DEXA T -2.7 Z -0.2 at spine
Primary hyperparathyroidismGuidelines - when to operate
Serum calcium > 2.80 mmol/L (Actually >0.25 mmol/L above reference range).
Osteoporosis BMD T-score <-2.5 at any site, or previous fragility fracture.
Renal stones
Age <50
Bilzekian et al, J Clin Endo Metab 2009, 94, 335-339.
Primary hyperparathyroidismReasons to operate
Symptoms Nausea. Thirst. Fatigue. Aches. Constipation.
Progressive hypercalcaemia Risk of future symptoms or hospital admission.
Osteoporosis
Renal stones
Cardiovascular disease??
Primary hyperparathyroidismReasons not to operate
Symptoms Vague. Conflicting evidence of benefit.
Progressive hypercalcaemia Rare in prospective studies - less than 5%.
Osteoporosis Often criteria met solely due to age. No proof of fracture reduction. Similar BMD benefit to bisphosphonates. Estimated absolute benefit is low - around 1:100 or less
Too much medicine? Prevalence tripled in 10 years as a result of more blood tests.
Primary hyperparathyroidismNon-surgical treatments
Vitamin D Not evidenced, sounds plausible.
Bisphosphonates Good evidence for # prevention though not tested in PHPT. Can lower sCa slightly – would not use for this purpose.
Cinacalcet Now licensed for PHPT where parathyroidectomy is inappropriate Cost £125-350 per month Lowers sCa by 0.25-0.3 mmol/L (perhaps more in more severe cases) No benefit on BMD demonstrated
Surgery for “asymptomatic” hyperparathyroidism - 1
Location Sweden, Norway, Denmark.
Subjects 191 patients with PHPT No parathyroid bone disease Calcium 2.6-2.85 No previous neck surgery Age 50-80 No renal impairment (creat>130) No interfering meds (thiazides etc) No kidney stones No MEN/familial hypercalcaemia No psych disorders
Intervention Surgery or observation
Follow-up 2 years
Bollerslev et al, J Clin Endo Metab 2007, 92, 1687-1692.
Outcomes
Bollerslev et al, J Clin Endo Metab 2007, 92, 1687-1692.
Surgery Observation
N 96 95
Age 64 64
Female/male 83/13 82/13
Baseline calcium 2.70 2.69
Calcium change -0.30 -0.02
Baseline creatinine 82 81
Final creatinine 0 0
BMD lumbar 1.09 1.06
BMD change +0.04 -0.04
Fractures Not reported
Outcomes
Physical component of SF36 – fell in both groups, no difference between groups.
Mental component of SF36 – fell in both groups, no difference between groups.
Surgery for “asymptomatic” hyperparathyroidism - 2
Ambrogini et al, J Clin Endo Metab 2007, 92, 1687-1692.
Location Italy.
Subjects 50 patients with PHPT No parathyroid bone disease Calcium 2.55-2.8 No kidney stones 24-hr urine calcium<10mmol No osteoporosis Age 50-75 No neck surgery No recent menopause No MEN/familial hypercalcaemia No major renal impairment
Intervention Follow-up Surgery or observation 1 year
Outcomes
Bollerslev et al, J Clin Endo Metab 2007, 92, 1687-1692.
Surgery Observation
N 24 26
Age 64 65
Female/male 22/2 24/2
Baseline calcium 2.55 2.55
Calcium change “Normalised” +0.05
Baseline creatinine clearance 93 93
Final creatinine clearance “Stable” 98
BMD lumbar 0.85 0.83
BMD change +4% -1%
Fractures Not reported
Outcomes
Solid line – surgery Dashed line - observation
Natural history of untreated PHPT
No really good long-term studies.
Surgery vs observation trials (as before) Bollerslev (Swedish study)
- tiny drop -0.02 over 2 years Ambrogini (Italian study)
- small rise +0.05 over 1 year
Natural history of untreated PHPT
PEARS study – parathyroid epidemiology and audit research study, Dundee
Records linkage – lab data to hospital records
Definition of PHPT• Serum calcium >2.55 x 2 with PTH>3 (ref 1-6.9)• Serum calcium >2.55 x 1 with PTH>6.9Definition of progression• Serum calcium 2.90• Serum calcium rise of 0.2 mmol/L
Yu et al, Q J Med 2011, 104, 513-521.
Natural history of untreated PHPT
Mean calcium clearly fell
Individual progression• 13% of total showed any.• 1% of total showed
sustained progression.
Possible problems• Was it really hyperpara?• Does it apply to more
severe hyperpara?
Yu et al, Q J Med 2011, 104, 513-521.
Osteoporosis
http://www.iofbonehealth.org/epidemiology. http://www.cdc.gov/nchs/data/nhanes/databriefs/osteoporosis.pdf . Both accessed 27th June 2014.
Prevalence increases with age• 30% of post-menopausal
women in Europe have osteoporosis.
• 87% of US women aged over 80 have osteopenia or osteoporosis
Fracture reduction
No RCT evidence for fracture reduction
Retrospective studies• Fewer fractures in surgically- versus medically-treated• But obvious confounders
Non-surgically treated were older and frailer
What about BMD?• RCT evidence shows 5-8% benefit after surgery• What does that mean?
Fracture risk estimation
No RCT evidence for fracture reduction
Retrospective studies• Fewer fractures in surgically- versus medically-treated• But obvious confounders
Non-surgically treated were older and frailer
What about BMD?• RCT evidence shows 5-8% benefit after surgery• What does that mean?
Primary hyperparathyroidismReasons not to treat
Symptoms Vague. Conflicting evidence of benefit.
Progressive hypercalcaemia Rare.
Osteoporosis Criteria met solely due to age. No proof of fracture reduction. Similar BMD benefit to bisphosphonates. Estimated benefit is low - around 1% absolute risk reduction.
Too much medicine? Prevalence tripled in 10 years as a result of more blood tests.
What treatment?
Primary hyperparathyroidismInvestigations
Bloods Calcium (high). Phosphate (low or low-normal). PTH (high or normal). Liver (alk phos often high but not diagnostic). Vitamin D (usually low and very occasionally confounds diagnosis).
Urine 24-hour urine calcium indices (see later).
Renal USS Only in patients with history suggestive of stones.
DEXA May influence surgery, or prompt bisphosphonate treatment.
Question
Roberta has this: Treatment:• Age 69 Keen to have surgery• Polyuria, fatigue, aches No contra-indications• Calcium 2.81 mmol/L• PTH 7.2 pmol/L SestaMIBI scan:• Vit D 50 nmol/L No apparent adenoma• 24-hr urine Ca 6.8 mmol• eGFR 51 What next?• DEXA T -2.7 Z -0.2 at spine
Answer
Roberta has this: Treatment:• Age 69 Keen to have surgery• Polyuria, fatigue, aches No contra-indications• Calcium 2.81 mmol/L• PTH 7.2 pmol/L SestaMIBI scan:• Vit D 50 nmol/L No apparent adenoma• 24-hr urine Ca 6.8 mmol• eGFR 51 What next?• DEXA T -2.7 Z -0.2 at spine Operate
Or further localisation studies
Primary hyperparathyroidismLocalisation studies
What is the aim?
• Exclude retrosternal/ectopic adenoma
• Identify solitary parathyroid adenoma vs multiple adenomata vs hyperplasia
• Least possible surgery
Primary hyperparathyroidismLocalisation studies
Conventional (Kochers) incision• Originally 8-10cm• Eventually reduced to 4-6cm
Minimal access• Arbitrary definition• E.g. below 2.5cm
Primary hyperparathyroidismMIBI scan
Theoretically:• 90% sensitivity, 98% specificity• 87% are solitary adenomas• 9% hyperplasia• 3% multiple adenomas• <1% cancer• Therefore, 78% of patients (90% of
87%) are candidates for unilateral neck exploration
Reality:• Often do not localise• Equipment dependent• Affected by MNG
Parathyroid surgeryExeter
Parathyroid SestaMIBI
LateralisingWith no pointers to secondary hyperpara Not lateralising (appropriate PTH, PO4, eGFR) Or possibility of secondary
hyperparaUnilateral neck exploration Examination of both parathyroids Bilateral exploration
One abnormal Both abnormal Remove and close
Primary hyperparathyroidismOther localisation studies
Ultrasound
Sesta-MIBI - SPECT/CT
Parathyroid venous sampling
Minimally-invasive radioguided parathyroidectomy (MIRP) (MIBI injection, Geiger counter to find active parathyroids)
Intra-operative PTH
Post-op hypocalcaemia
Frequency• About 10-30% of cases• More likely with… severe hypercalcaemia
vitamin D deficiencyvery high PTHmulti-gland surgery
Prevention• Vitamin D repletion• Cinacalcet?• Bisphosphonates?
Post-op hypocalcaemiaPost-operative monitoring
Check corrected calcium 1st post-op day
Ca >2.2 Ca 2.0 – 2.19and/or more than 0.2 mmol/l lower than pre-op
Ca 1.7 – 1.99 * Ca <1.7 *or markedly symptomatic
Low risk groupRepeat Ca day 7
High risk groupRepeat day 3-4 and day 7
Start or Continue pre-op Adcal D3 Repeat in 2 days
Start 1alpha calcidol1mcg odand Sandocal1000 bd
Give iv calcium gluconate10ml. Repeat serum calcium after 6 hours.Commence 1 alpha calcidol 2 mcg od and Sandocal 1000 bd
Ca 2.0 – 2.19 Repeat after 3 daysIf Ca >2.0repeat day 7
Review 6 weeks by Endocrinology service
Ca 1.7 – 1.99Increase 1 alpha to 2mcg od.
Repeat daily until Ca >2.0
Ca >2.2
Rob Dyer – draft, 2012.
Question
Jake has this: What investigations?• Age 39• Polyuria, fatigue, aches• Calcium 2.85 mmol/L• PTH 78.2 pmol/L• Vit D 52 nmol/L• 24-hr urine Ca 6.8 mmol• eGFR >90• DEXA T -0.4• Surgery shows four-gland hyperplasia
Answer
Jake has this: What investigations?• Age 39• Polyuria, fatigue, aches MEN guidelines 2012• Calcium 2.85 mmol/L 2+ MEN-associated tumours• PTH 78.2 pmol/L 1st deg rel of known MEN1• Vit D 52 nmol/L Parathyroid adenomas <30• 24-hr urine Ca 6.8 mmol Multigland parathyroid disease• eGFR >90 Gastinoma• DEXA T -0.4 Pancreatic NET• Surgery shows four-
gland hyperplasia
Prevalence of MEN in hyperparathyroidism
High penetrance (95%+) of PHPT in known MEN by age 50• Often said no need to consider MEN if diagnosed over 50
But would PHPT be diagnosed before 50 if MEN not known?• E.g. develops age 45, diagnosed age 55?
Prevalence of MEN in PHPT• Uchino et al – 25% menin mutations• Yip et al – 4% prevalence but 26% if hyperplasia• De Laat et al – 7% prevalence
Always ask about FH of hypercalcaemia, renal stones, brain tumours, neck surgery, ulcers, pancreatic tumours
Primary vs secondary vs tertiary hyperparathyroidism
Divide calcium by 4 to get mmol/L
Div
ide
PT
H b
y ab
out
10 t
o ge
t pm
ol/L
Primary SecondaryParathyroid adenoma Renal failure
Impaired PO4 excretionHigh PTH Impaired Vit D activation
High calcium High PTHLow phosphate Normal or high phosphate
Normal or low calcium
Secondary hyperparathyroidism
Secondary hyperparathyroidism
High or normal phosphateLow or normal calciumHigh PTHeGFR below 60
Levi
n –
Am
J K
id D
is 1
991,
34,
125
-134
.
NICE 2008 guidelines• Monitor in CKD 4/5 (e.g. in diabetes clinics)• Measure Ca, PO4, PTH• Decide frequency of monitoring by results and clinical
circumstances. Seek specialist opinion. (Just do it annually?).
• Cholecalciferol or ergocalciferol for CKD 1-3b• Alfacalcidol or calcitriol for CKD 4-5
Secondary hyperparathyroidismmanagement
AKA refractory secondary hyperparathyroidism• Development of autonomous nodular parathyroid hyperplasia• Hypercalcaemia
Indications for surgery• Severe hypercalcaemia/hyperphosphataemia• Parathyroid bone disease• Extraskeletal calcification• Unexplained symptomatic myopathy• WITH PTH>800 pg/mL (88 pmol/L) (all of the above can
develop in dialysis patients for other reasons, so must confirm presence of hyperparathyroidism)
“Tertiary” hyperparathyroidism
Surgical options – no agreement which is best
• Total parathyroidectomy (unpopular)
• Total parathyroidectomy with auto-transplantation into forearmTheoretically – if recurrent, no need for re-explorationof neck. But persistent hypercalcaemia after removal of arm graft is quite common, i.e. it was in the neck all along.
• Subtotal parathyroidectomy (leaving 40-60mg of the least hyperplastic gland)
“Tertiary” hyperparathyroidism
Persistent hyperparathyroidism• Nodular hyperplasia from prolonged secondary hyperpara
Normal renal function• Eliminates resistance to PTH due to uraemia• Restores normal 1-hydroxylation of vit D
Hypercalcaemia after renal transplant
Causes of hypercalcaemia
Malignancy 90% ofPrimary hyperparathyroidism all cases
Other causesFamilialDrugs: lithium, thiazides, activated vitamin DGranulomatous diseases: sarcoid etcMilk alkali syndromeHyperthyroidismProlonged immobilisation
Familial benign (hypocalciuric) hypercalcaemia
CaSR mutation• Body “sees” a high calcium level as normal• Present from birth• One explanation for failed parathyroid surgery
Misnamed• Normocalciuric (just lower than expected)
In most cases:• PTH not very high• Urine calcium not elevated• Calcium:creatinine clearance ratio <0.02• No osteoporosis• Asymptomatic
Familial (benign) (hypocalciuric) hypercalcaemia
PHPT FBHH
PTH pmol/L 50% above 8-9 50% below 395% below 8.599% below 9.1
24-hr urine calcium mmol
70% above 6.5 50% below 2.395% below 6.599% below 9.0
Calcium:creatinine clearance ratio
98% below 0.02 65% above 0.0295% above 0.06
Gunn et al Ann Clin Biochem 2004, 41, 441-458 Christensen et al Clin Endo 2008, 69, 713-720.
CCCR>0.02 excludes FHH.Consider genetic testing if <0.02 (NB only 70% of familial cases are positive on genetic tests).
Familial benign (hypocalciuric) hypercalcaemia
Severe cases are reported• Homozygous mutations• Severe symptomatic hypercalcaemia• Osteoporosis• Very high PTH
Parathyroid jaw tumour syndrome
• Rare• Autosomal dominant• Parathyroid tumours ~15% carcinomas• Fibro-osseous tumours of jaw bones• Plus loads of other tumours – Wilm’s, renal cysts, renal hamartomas,
renal cortical adenomas, papillary renal cell carcinomas, pancreatic adenocarcinomas, testicular seminomas, uterine.
Lithium
Causes hyperparathyroidism Expect PTH to be elevated. If low PTH - look for cancer.
Also causes diabetes insipidus Severe hypercalcaemia causes dehydration. DI causes dehydration. Dehydration worsens hypercalcaemia.
Nightmare combo Mania with severe hypercalcaemia and renal impairment.
Lithium – prevalence of hypercalcaemia
Lally et al 5% of 33 patients
Twigt et al 15.6% of 314 patients Duration of Li therapy was main predictor No hypercalcaemia in control group of non-Li psych patients
Bendz et al 6% incidence in 142 patients over 19 years 13 consented to trial of Li withdrawal – all ineffective
Ir Med J 2013 106 15-17. Int J Bipolar Dis 2013 1 18. J Int Med 1996 240 357-365.
Lithium – management of hyperparathyroidism
Surgery Adenoma vs hyperplasia
Withdrawal of lithium Mainly ineffective (short-term studies only) But worth a try
Thiazides
Effects● Small increase (1-2%) in serum total calcium● Small increase (10-20%) in PTH● Little or no effect on ionized calcium● Reduction in urinary calcium excretion
Does it matter?● Probably not● Most cases of hypercalcaemia with thiazides turn out
to be coincidental primary hyperparathyroidism
Rejnmark et al. Euro J Clin Invest 2003, 33, 41-50. Wermers et al, Am J Med 2007, 120, 911.
Thiazides and hypercalcaemia –practical points
Stop the thiazide● Recheck calcium and PTH● Is there malignancy?● Is there primary hyperparathyroidism?
Could restart it if all OK● E.g. if mild primary hyperpara for “watch and wait”
No cause found. What next?
HypercalcaemiaLow or non-elevated PTHNo evidence of malignancyNo lithiumNo thiazidesNo calcium/vit D supplementsNormal thyroid function
Rarer stuff
Granulomatous diseases: sarcoid etc CT chest. s-ACE??
Milk alkali syndromeProlonged immobilisationCirrhosis I don’t know the mechanism
Adrenal insufficiency I don’t know the mechanism Primary or secondary
Acute management of hypercalcaemia
When is admission required?• Definitely if sCa>3.5 mmol/L• 3-3.5 mmol/L – depends on trend, age, frailty, renal
function etc
Acute management of hypercalcaemia
1. Hydration• 4-6 litres 0.9% saline over 24 hours• Loop diuretics for fluid overload – not effective at lowering
calcium2. IV bisphosphonate• Zoledronate 4mg• Pamidronate 30-90mg3. Alternatives• Prednisolone 40mg (inhibits 1,25-D production – useful in
granuloma, lymphoma, 25-D intoxication)• Cinacalcet• Calcitonin
Society for Endocrinology 2013 guideline
Hypocalcaemia
Causes of hypocalcaemia
EDTA contaminationLow magnesiumRespiratory alkalosisPPIVit D deficiencyHypoparathyroidism - primary - post-surgical - pseudo
EDTA contamination
EDTA leakage into biochem tube causes... High potassium Low calcium, magnesium, alk phos
Fill biochem tubes before haematology tubes
Hypocalcaemia due to hypomagnesaemia
Low magnesium is common in…● elderly● diarrhoea● diuretics● patients taking PPIs
Treatment● stop diuretics● stop PPIs● oral magnesium supplements (limited efficicacy)
○ Maalox or Mucogel - 35 mL/day in divided doses○ magnesium glycerophosphate - 4 tabs per day
● IV replacement
What level of hypomagnesaemia requires treatment?
When you write a guideline, it always ends up more cautious than your real practice● Many guidelines say Mg<0.5 mmol/L requires urgent IV treatment
My comments● Hypomagnesaemia seems common in general medical patients● It definitely is common in frail elderly● In 169 long-term geriatric care patients, 53% had sMg<0.45 mmol/L,
18% had sMg<0.35 mmol/L● I would treat principally if symptomatic or hypocalcaemic or
hypokalaemic
Alinzon et al, Arch Geront Ger 2010, 51, 36-40.
Hypocalcaemia due to alkalosis
Normal● albumen carries negative charge● some albumen is bound to positive H+
● some Ca2+ is bound to remaining albumen● free/ionized Ca2+ is biologically active
Hyperventilation● respiratory alkalosis due to blowing off CO2
● lower H+ concentration● more negative charged albumen free to bind Ca2+
● free/ionized Ca2+ falls● total sCa does not change
When should we measure ionized calcium?
Ideally – always
In the real world● if you have a calcium abnormality but struggling to make a diagnosis● if symptoms suggest hypocalcaemia but normal total sCa
Hypocalcaemia due to vitamin D deficiency
Seen in…● malnutrition● elderly● institutionalised● coeliac / malabsorption / short bowel
Treatment● see formulary● Adcal D3 or Calcichew D3 (400 units per tab)● Fultium D3 (800 units per tab)● OTC - at least 2000 units per day, 8p per day from H&B
Oral: Hypocalcaemia is rare, well under 0.5% Usually occurs after a few weeks Transient
IV high dose: Hypocalcaemia more common but still rare
Most cases have other risk factors: + coeliac disease + hypoparathyroidism
Hypocalcaemia due to bisphosphonates
Gain of function CaSR mutation• Consider if diagnosed young, and never had normal calcium• Family history helpful. (NB affected relatives likely undiagnosed).
No simple characterisation• Earliest reported cases had marked hypocalcaemia, low PTH and
clearly elevated CCCR. (Perhaps that’s why they were identified).• Confirmed familial cases with no symptoms and normal CCCR.• Treat if symptomatic e.g. seizures• Many case reports of calcification of skull, brain, kidney, cataract• Treatment will increase calcium throughput
Familial (hypercalciuric) hypocalcaemia
Question
Bill has this:• Calcium 1.4 mmol/L• PTH 76 pmol/l (1.6-6.9)
What is the diagnosis?
Answer
Bill has this:• Calcium 1.4 mmol/L• PTH 76 pmol/l (1.6-6.9)
Diagnosis could include:• Vitamin D deficiency• Renal failure• Rhabdomyolysis• Pseudohypoparathyroidism• etc
Hypoparathyroidism
Causes• Usually post-surgical• Rarely, primary or pseudo
Features• Low calcium• High phosphate• High PTH• Vitamin D replete• Normal renal function
Vitamin D from skin and diet 25-hydroxylase
25(OH)-D – inactive (?)
1-OHase
PTH effects on the kidney1.Stimulates activation of vit D.2.Promotes phosphate excretion.3.Reduces calcium resorption.
1,25(OH)2-D effects on kidneyIncreases Ca resorption
1α-hydroxylationStimulated by Inhibited by PTH 1,25(OH)2-D Low PO4 High PO4
PTH effect on boneCalcium export
PTH productionMain stimulus is low Ca2+.Inhibited by 1,25(OH)2-D.Mg required.
Calcitonin productionMain stimulus high Ca2+ (ionized>1.15) – also glucagon, gastrin, ß-adrenergic agonists (?reason for low Ca in acute illness)
Calcitonin effects on bone• inhibits osteoclast
resorption• thereby lowers Ca and PO4
• no effect on Mg
1,25(OH)2-D effects on gutIncreases Ca2+ and PO4
absorption
Vit D direct effect on bone?Unclear
Parathyroid hormone
Calcitonin
1,25-OH2-D
Hypoparathyroidism
Lack of PTH • Kidneys don’t retain calcium• Kidneys don’t excrete phosphate
Activated vitamin D treatment• Increase calcium absorption from gut• Increase phosphate absorption from gut
Overall effect• Forced intestinal calcium absorption• Increased renal calcium throughput• High calcium x phosphate product• Nephrocalcinosis (and other calcifcation)
Hypoparathyroidism
Treatment targets• sCa around lower limit of normal• “Non elevated” urine calcium• NB this may not be achievable – average 24-hr urine calcium in
appropriately-treated patients is around 8-8.5 mmol.
rPTH(1-84) therapy• Once daily injection• Achieved reduction in use of calcium and active vit D• Similar sCa and uCa levels - questionable benefit• High cost (Preotact licensed for osteoporosis, £4000 per year)
Mannstadt et al, Lancet 2013, 1, 275-283..
Pseudohypoparathyroidism
PTH inaction – defect downstream of PTH receptor
Type 1a Type 1b Pseudopseudo
Transmission Maternal. GNAS1 mutation. Loss of function in G-protein.
Methylation. Mostly sporadic, or maternal.
Paternal. GNAS1 mutation.
Kidney PTH resistance
Yes, hypocalcaemia Yes, hypocalcaemia No, normal
Bone PTH resistance
Yes, AHO No, hyperparathyroid bone disease
Yes, AHO
Other hormones
Can see resistance to TSH, ADH, FSH/LH, ACTH, GHRH
Maybe
Treatment Activated vitamin D Activated vitamin DParathyroidectomy
Pseudohypoparathyroidism 1b
RN, diagnosed age 27• Presents with knee pain• X-ray shows cystic changes in bones• (Diagnosis not considered by ortho)• Later…• sCa 1.37• sPO4 1.67• PTH 76• Vit D normal
Pseudohypoparathyroidism 1b
RN - Treatment• Alfacalcidol to normalise PTH• PTH came down to 2• Calcium up to 2.3-2.9• Creatinine later up 60 to 114• USS - nephrocalcinosis
• Alfacalcidol reduced• Creatinine down to 70• Calcium 2.0-2.3• PTH 25-30• Urine calcium 2.4 mmol/24h• X-ray stable
• Observe• Consider parathyroidectomy